The structure of the most recently discovered, biologically highly active prostaglandin, PGI2 or prostacyclin, is correctly predicted on biogenetic grounds, and a general synthesis starting with prostaglandins of the F2a series is reported. Starting with the biologically active 13,14-dehydro-PGF a, the synthesis involves formation of a 5-bromo-6,9a-epoxy derivative, followed by esterification and dehydrobromination of the methyl ester to form the prostacyclin structure. The stereochemistry at C-5 and C-6 of all reported products is assigned on the basis of experimental findings and mechanistic reasoning. 13,14-Dehydroprostacyclin methyl ester is considerably more stable at pH 7.5 than prostacyclin. It inhibits platelet aggregation induced by a variety of agents and causes an increase in renal blood flow in the dog at nanomolar levels.
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In recent publications, Moncada et al. (1) and Gryglewsky et al. (2) reported the conversion of the prostaglandin (PG) endoperoxides PGG2 and PGH2, by pig and rabbit aorta microsomes, to a new unstable prostaglandin, which they named PGX. This substance was characterized by a spectrum of biological activities different from that of all other prostaglandins, notable among which were its powerful inhibition of platelet aggregation and relaxation of arterial strips. Its chemistry was elucidated by Johnson et al. (3) who assigned to itstructure I and named it prostacyclin (Fig. 1 ). It is of rhore than casual interest that prostacyclin or PGI2 (renamed in keeping with well-established usage of capital letters for designating prostaglandins) was also formed by rat stomach fundus microsomes (2) , from which Pace-Asciak and Wolfe (4, 5) had previously isolated two substances to which they had assigned structures II and III on the basis of spectroscopic evidence.* More recently, Pace-Asciak isolated from the same source a third substance, IV, which is the hemiketalic form of 6-oxo-PGF1,, (6) 
The lack or low level of activity of II in the gerbil colon assay (5) led most observers at the time to consider these substances as curiods aberrations of prostaglandin biosynthesis. The discovery of the prominent biological properties of prostacyclin and the finding that it was readily hydrolyzed to the inactive IV served to propel this neglected structural type to center stage of prostaglandin research.
We had long been pondering the question of the significance Abbreviations: PG, prostaglandin; TX, thromboxane; NMR, nuclear magnetic resonance; TMS, trimethylsilyl; IR, infrared; la, (5R,6R)-9-deoxy-5-bromo-6,9cx-epoxy-13,14-dehydro-PGF1,,; lb, (5S,6S)-isomer of la; TLC, thin-layer chromatography; 2a, (5S, 6R)-9-deoxy-5-hydroxy-6,9ae-epoxy-13,14-dehydro-PGF1,, multiplicities: s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). Infrared (IR) spectra were recorded on a Perkin Elmer 137 spectrometer in CH2CI2. Spectra were calibrated against the polystyrene 6.238 jim absorption. Rotations were measured on a Perkin Elmer model 141 polarimeter using a 10-cm path length in CHCI3. Mass spectra were recorded on a Finnigan 1015 quadrupole spectrometer equipped with a vpc inlet; spectra were collected and processed by a Systems Industries Computer Interface System/150 and are expressed as percentage of the base peak (in parentheses). Microanalyses were performed by Baron Consulting Co., Orange, CT.
(5R,6R)9Deoxy-5-bromo-6,9a-epoxy-13,14-dehydro-PGFIq, (la) and Its (5S, 6S) Isomer (lb). To a solution of 0.203 g (0.58 mM) of 13,14-dehydro-PGF2(, in 20 ml of dry acetonitrile was added 0.115 g (0.65 mM) of N-bromosuccinimide. The solution was stirred at room temperature until thin-layer chromatography (TLC) showed disappearance of starting material (2-4 hr), and then the solution was concentrated to dryness under a stream of nitrogen. The residue was washed with four 2-ml portions of 5% NaHCO3; the combined aqueous fractions were extracted with CH2CI2 (3 X 2 ml), acidified with 2 M HlCl, and 2 co2 again extracted with CH2Cl2 (4 X 2 ml). This last extract was dried over MgSO4, concentrated, and chroinatographed on 18.6 g of silica gel (1 X 56 cm column, washed with CHC13). Elution was carried out with 2% MeOH/HOAc/I2O (90:10:6.5, vol/ vol) in CHC13 in 5-ml fractions. Fractions 13-18 (lb, 50 mg): NMR 4.51 (ra, 1H, H-9), 4.35 [t (7) (5Z)9-Deoxy-6,9a-epoxy-13,14-dehydro-PGF2a (13,14-Dehydroprostacyclin) Methyl Ester (3). A mixture of 35.1 mg (0.079 mM) of the methyl ester of the bromo acid la and 44.5 mg (0.29 mM) of DBU was diluted with 0.30 ml of toluene, degassed with N2, and immersed in a 98-100°oil bath for 2 hr. The solution was diluted with 0.50 ml (4:1, vol/vol) of hexane/ethyl acetate, and the resulting precipitate was washed with two 0.25-ml portions of the same solvent. The combined extracts were washed rapidly with two 1-ml portions of cold NaCl-saturated 0.1 M HCl, dried over Na2SO4, and concentrated under nitrogen to yield 27.8 mg (96.5%) of enol ether ( This spectrum shows many similarities with that of prostacyclin methyl ester (3), making allowance for the presence of the 13,14 triple bond.
,(4EX6S)9 -Deoxy-6,9a-epoxy4,5;13,14-bisdehydro-PGF1a
Methyl Ester (4) . A mixture of 10.5 mg (0.024 mM) of bromo ester lb-ester and 14.9 mg (0.098 mM) of DBU in 0.1 ml of toluene was degassed ahd heated as above for 3 hr. Work-up gave 8 mg of a pale brown oil, which was further purified by preparative TLC 1, M+), 421 (1, M-OCH3), 359 (2, 421-CH20-CH30H Acid Hydrolysis of (5Z)9-Deoxy-6,9a-epoxy-13,14-dehydro-PGF2a Methyl Ester (13-Dehydroprostacyclin Methyl Ester, 3). Solutions were prepared by dissolving 0.1-mg samples of 3 in 40 ,Al of acetonitrile, and then adding 10,gl of an appropriate aqueous acid solution at 250. Aliquots were examined by TLC (EtOAc/silica gel) at various times. Using HC104 (0.01 or 0.001 M) or 1 M HOAc as the acidic medium, we noted complete disappearance of 3 and appearance of 6-keto-13-dehydro-PGF1,, methyl ester after 2 min. Using 0.1 mM HC04 or 0.1 M HOAc, we noted ca 50% hydrolysis after 2 min and complete disappearance after several hours.
The hydrolyzed samples were evaporated, treated with MeONH2-HCl in pyridine, and then examined by gas chromatography/mass spectroscopy: m/e 612 (2, M-CH3), 537 ( RESULTS AND DISCUSSION The synthesis described in this paper mimics the proposed biosynthesis of prostacyclin in that it achieves formation of the tetrahydrofuran ring by reaction of the 5,6-double bond with the 9a'-hydroxyl group. The relevant intermediates as well as derivatives essential for proof of structure are shown in Fig. 2 .
Thus, treatment of 13,14-dehydro-PGF2a with N-bromosuccinimide in acetonitrile yielded a mixture of bromoethers la and lb in a 4:1 ratio, which were readily separatedby chromatography from each other and from a small amount of the 15-ketone of la. Neither of the isomeric bromides showed NMR signals for the vinyl protons at C-5 and C-6 present in the starting material. Instead, there appeared two new multiplets at 4.00 and 4.24 6 (major isomer) and 3.83 and 4.22 6, indicating methine protons at these same carbons compatible with the proposed bromo ether structures. The fact that la and lb are 5-rather than 6-membered ethers was evident from the mass spectra of their bis-trimethylsilyl ether trimethylsilyl esters and bis-trimethylsilyl ether methyl esters, all of which showed an ion at mass 395 indicating cleavage between C-5 and C-6 with loss of C-1 to C-5. This structural assignment was confirmed after conversion of the acids la and lb to two isomeric 6-lactones 2a and 2b on treatment with DBU in toluene, each of which likewise formed an ion at 395, in this case as one 64 the major peaks. Formation of the lactones occurs by displacement of bromide by carboxylate anion with inversion at C-5. Their 11,15-diacetates, which showed the five low-field methine protons as separate NMR resonances, provided structural confirmation.
The assignment of structures la and lb to the major and minor isomers, respectively, is not a trivial matter. Certainly, trans-addition to the cis-double bond would be expected to occur giving rise to two threo structures. An examination of molecular models predicts a less crowded transition state for la, which on this basis should represent the major product. This argument appears to be in contradiction to the results obtained when the methyl esters of la and lb were subjected to dehy-drobromination with DBU in toluene at 1000, which constitutes the second and final step of our synthesis. In this reaction, the major product la methyl ester afforded the enol ether 3(13,14-dehvdroprostacyclin) in 97% yield, so formulated because of the appearance of a single NMR signal at 4.21 6 characteristic of vinyl ether protons, coupled with the disappearance of the methine resonances for H-5 and H-6, and a strong enol ether absorption at 6.09/ in the IR. The mass spectrum shows several bands confirming this structure, notably a strong ion at 421 indicating loss of a fragment corresponding to C-1 to C-3. Hydrolysis of the enol ether 3 was complete after 5 min in 2 mM HCIO4 in acetonitrile/water (4:1 vol/vol) at 250, and yielded the expected 6-keto ester. The product was identified by conversion into the methoxime and comparison of its mass spectrum with that reported for the methoxime of 6-keto PGFJ,, methyl ester (6) . The formulation of 3 as the Z ether is based on the premise that trans elimination of HBr constitutes the preferred course of the reaction. Reaction of the minor bromo ether lb with DBU afforded a double-bond isomer of 3 to which structure 4 is assigned because of the presence of two trans vinyl protons at 5.52 and 5.72 6 coupled on one side to a methine and on the other to two methylene protons. It is this difference in the dehydrobromination reaction of the two bromo ethers that appeared, at first sight, to be at variance with the assignments of structures la and lb: the 6a (endo) methine proton of the former should prove less accessible to the base than the 60 (exo)-proton of Ib; that is, la should give rise to 4 and lb to 3.
There is, however, another interpretation of the results of the dehydrobromination reaction that is in accord with our previous assignment. If, instead of attack by the external base, intramolecular deprotonation occurred via the Ila hydroxylate anion, the proximity of the latter to the 4-methylene protons of lb could, by preferred abstraction of the 4-pro-S proton, give rise to 4, whereas in the case of la that proton would be inaccessible to the internal base. To test this hypothesis, we converted lb into the 11,15-bismethoxymethyl ether and subjected the latter to reaction with DBU. In this case, the 11,15-bis ether of 3 was formed by attack of the external base on the 6/-proton. § This experiment provides evidence in favor of intramolecular proton abstraction as long as a free 1 lca-hydroxyl group is available. It also reveals the interesting fact that intramolecular abstraction of the 4-proton is preferred over bimolecular formation of the enol ether by abstraction of the more readily accessible 6/-proton.
The half-life of natural prostacyclin in Tris buffer at pH 7.6 is approximately 10 min (3); this is most unusual for an enol ether. We have examined the stability of the methyl ester 3 under these same conditions and found it to be essentially unchanged over a 24-hr period. This radical difference is not likely to be due to the presence of the 13,14-triple bond but rather to that of the methyl ester grouping. One may speculate that internal delivery of the carboxyl proton present in equilibrium at pH 7.6 might be responsible for this considerable enhancement in the rate of hydrolysis of free prostacyclin.
-13,14-Dehydroprostacyclin methyl ester (3) was examined (C. L. Malmsten, S. Hammarstrom, J. Fried, and J. Barton, unpublished data) for its capacity to inhibit aggregation of human platelets induced by a variety of agents (7) and was found to possess potency similar to that reported for natural prostacyclin (3). Thus, the inhibitory dose (ID50) was 3 ng/ml when induced with arachidonic acid, 2.5 ng/ml with ADP, 1.2 ng/ml with collagen, and 8 ng with PGG2. When compared with PGE2, 3 was 10 times more potent as an inhibitor of ADP-induced aggregation. Compound 3 was also tested (T. Paustian, J. Fried, B. M. Chapnick, L. P. Seigen, A. L. Hyman, and P. J. Kadowitz, unpublished data) for its ability to affect renal blood flow in anesthetized dogs (10) . Dose levels of 3 low enough to attain a concentration of 1 ng/ml in renal arterial blood produced a 20% increase in renal blood flow.
The levels of biological activities reported here for compound 3 suggest that it possesses the characteristic structural features of prostacyclin. Published data (3) support structure I for prostacyclin, which lacks definition only as far as the stereochemistry of the double bond is concerned. The synthetic route described in this paper defines 3 as possessing the Z structure. We therefore favor the Z isomer of I as representing the structure of prostacyclin.
